Galmed Pharmaceuticals 8/28/2024 Earnings Report

Galmed Pharmaceuticals EPS Results

• Actual EPS: $2.16
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Galmed Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Galmed Pharmaceuticals Announcement Details

• Date: 8/28/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Galmed Pharmaceuticals (NASDAQ:GLMD) Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials.

In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders. The company leverages strategic partnerships for manufacturing and formulation development while pursuing regulatory approvals in key markets. Its clinical trial activities span North America and Europe, with trial sites designed to support potential future commercialization in regions where NASH represents a substantial unmet medical need.

Founded in 2001 and headquartered in Tel Aviv, Israel, Galmed maintains corporate offices in the United States to facilitate interactions with regulatory agencies, clinical investigators and potential commercial partners. The company’s leadership team combines expertise in pharmaceutical development, hepatology and global commercialization strategy. Galmed Pharmaceuticals is publicly traded on the NASDAQ under the ticker symbol GLMD and remains committed to advancing therapies for patients suffering from progressive liver disease.